Results 131 to 140 of about 17,802 (285)

The effect of prolonged simulated non- gravitational environment on mineral balance in the adult male, volume 1 Final report [PDF]

open access: yes
Effect of prolonged bed rest with simulated weightlessness on mineral balance in male adult - Vol.
Bayers, J. H.   +4 more
core   +1 more source

Aggressive prostate cancer is associated with pericyte dysfunction

open access: yesMolecular Oncology, EarlyView.
Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero   +11 more
wiley   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

open access: yesMolecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia   +9 more
wiley   +1 more source

Editorial: Cardio-vascular Dysfunction and Physiological Manifestations Induced by Environmental Conditions

open access: yesFrontiers in Physiology, 2022
Marc-Antoine Custaud   +5 more
doaj   +1 more source

Motion sickness susceptibility under weightless and hypergravity conditions generated by parabolic flight [PDF]

open access: yes
Motion sickness susceptibility under weightless and hypergravity conditions generated by parabolic ...
Graybiel, A.   +3 more
core   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

open access: yesMolecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz   +15 more
wiley   +1 more source

USSR Space Life Sciences Digest, issue 31 [PDF]

open access: yes
This is the thirty first issue of NASA's Space Life Sciences Digest. It contains abstracts of 55 journal papers or book chapters published in Russian and of 5 Soviet monographs. Selected abstracts are illustrated with figures and tables from the original.
Garshnek, Victoria   +3 more
core   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

open access: yesMolecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed   +10 more
wiley   +1 more source

Publications of the NASA space biology program for 1980 - 1984 [PDF]

open access: yes
A listing of 562 publications supported by the NASA Space Biology Program for the years 1980 to 1984 is presented. References are arranged under the headings which are plant gravitational research, animal gravitational research, and general.
Pleasant, L. G., Solberg, J. L.
core   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

open access: yesMolecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy